Review of systemic treatment options for adult atopic dermatitis

Journal of Cutaneous Medicine and Surgery

Volumn 21, Issue 1, 2017, Pages 31-39

  Gooderham, Melinda ^a   Lynde, Charles W ^b,c   Papp, Kim ^d   Bourcier, Marc ^e   Guenther, Lyn ^f   Gulliver, Wayne ^g   Hong, Chih Ho ^h   Poulin, Yves ⁱ   Sussman, Gordon ^j   Vender, Ronald ^k  

^a QUEEN S UNIVERSITY   (Canada)

^b Lynde Dermatology   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d K Papp Clinical Research and Probity Medical Research   (Canada)

^e UNIVERSITÉ DE SHERBROOKE   (Canada)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

^g MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁱ UNIVERSITÉ LAVAL   (Canada)

^j UNIVERSITY OF TORONTO   (Canada)

^k Dermatrials Research   (Canada)

more..

Author keywords

Adults; Atopic dermatitis; Biologics; Dupilumab; IL 13; IL 4; Systemic therapy

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; DUPILUMAB; INFLIXIMAB; MEPOLIZUMAB; METHOTREXATE; OMALIZUMAB; RITUXIMAB; USTEKINUMAB; BIOLOGICAL PRODUCT; MONOCLONAL ANTIBODY;

ATOPIC DERMATITIS; BACK; CHIN; FACE; HAND; HUMAN; META ANALYSIS; NECK; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOTHERAPY; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; WRIST; ADULT; DERMATITIS, ATOPIC; QUALITY OF LIFE;

ADULT; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; BIOLOGICAL PRODUCTS; CYCLOSPORINE; DERMATITIS, ATOPIC; HUMANS; QUALITY OF LIFE;

EID: 85014366260     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.1177/1203475416670364     Document Type: Review

References (79)

1. Flohr C, Mann J. New insights into the epidemiology of childhood atopic dermatitis. Allergy. 2014;69:3-16.
2. Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol. 2013;132:1132-1138.
3. Harskamp CT, Armstrong AW. Immunology of atopic dermatitis: novel insights into mechanisms and immunomodulatory therapies. Semin Cutan Med Surg. 2013;32:132-139.
4. Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and subjective measure of disease activity. Acta Derm Venerol. 2000;80:430-434.
5. Roekevisch E, Spuls PI, Kuester D, Limpens J, Schmitt J. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systemic review. J Allergy Clin Immunol. 2014;133(2):429-438.
6. Deckers IA, McLean S, Linssen S, Mommers M, van Schayck CP, Sheikh A. Investigating international time trends in the incidence and prevalence of atopic eczema 1990-2010: a systematic review of epidemiological studies. PLoS One. 2012;7:e39803.
7. Bieber T. Mechanisms of disease: atopic dermatitis. N Engl J Med. 2008;358(4):1483-1494.
8. Spergel JM. From atopic dermatitis to asthma: the atopic march. Ann Allergy Asthma Immunol. 2010;105:99-106.
9. Eichenfield LF, Tom WL, Chamlin SL, et al. Section 1.Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70:338-351.
10. Holm EA, Wulf HC, Stegman H, Jemec GBE. Life quality assessment among patients with atopic eczema. Br J Dermatol. 2006;154:719-725.
11. Maksimović N, Janković S, Marinković J, Sekulović LK, Zivković Z, Spirić VT. Health-related quality of life in patients with atopic dermatitis. J Dermatol. 2012;39(1):42-47.
12. Bhatti ZU, Finlay AY, Bolton CE, et al. Chronic disease influences over 40 major life-changing decisions (MLCDs): a qualitative study in dermatology and general medicine. J Eur Acad Dermatol Venereol. 2014;28:1344-1355.
13. Higaki Y, Kawamoto K, Kamo T, Ueda S, Arikawa J, Kawashima M. Measurement of the impact of atopic dermatitis on patients' quality of life: a cross-sectional and longitudinal questionnaire study using the Japanese version of Skindex-16. J Dermatol. 2004;31:977-982.
14. Burckhardt CS, Anderson KL. The Quality of Life Scale (QOLS): reliability, validity, and utilization. Health Qual Life Outcomes. 2003;1:60.
15. Golics CJ, Basra MKA, Finlay AY, Salek S. The development and validation of the Family Reported Outcome Measure (FROM-16) to assess the impact of disease on the partner or family member. Qual Life Res. 2014;23:317-326.
16. Basra MK, Sue-Ho R, Finlay AY. The Family Dermatology Life Quality Index: measuring the secondary impact of skin disease. Br J Dermatol. 2007;156:528-538.
17. Basra MK, Finlay AY: The family impact of skin diseases: the Greater Patient concept. Br J Dermatol. 2007;156:929-937.
18. Schmitt J, Langan S, Deckert S, et al. Harmonising Outcome Measures for Atopic Dermatitis (HOME) initiative: assessment of clinical signs of atopic dermatitis: a systematic review and recommendation. J Allergy Clin Immunol. 2013;132:1337-1347.
19. Houtzager BA, Möller EL, Maurice-Stam H, Last BF, Grootenhuis MA. Parental perceptions of child vulnerability in a community-based sample: association with chronic illness and health-related quality of life. J Child Health Care. 2015;19(4):454-465.
20. Lewis-Jones S: Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract. 2006;60:984-992.
21. McKenna SP, Doward AC: Quality of life of children with atopic dermatitis and their families. Curr Opin Allergy Clin Immunol. 2008;8:228-231.
22. McKenna SP, Whalley D, Dewar AL, et al. International development of the Parents' Index of Quality of Life in Atopic Dermatitis (PIQoL-AD). Qual Life Res. 2005;14:231-241.
23. Ho RCM, Giam YC, Ng TP, et al. The influence of childhood atopic dermatitis on health of mothers, and its impact on Asian families. Pediatr Allergy Immunol. 2010;21:501-507.
24. Chernyshov PV, Jirakova A, Ho RC, et al. An international multicenter study on quality of life and family quality of life in children with atopic dermatitis. Indian J Dermatol Venereol Leprol. 2013;79:52-58.
25. Moore K, David TJ, Murray F, et al. Effect of childhood eczema and asthma on parental sleep and well-being: a prospective comparative study. Br J Dermatol. 2006;154:514-518.
26. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis. Section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(6):116-132.
27. Lynde C, Barber K, Claveau J. Canadian practical guide for the treatment and management of atopic dermatitis. J Cutan Med Surg. 2005;8(suppl 5):1-9.
28. Reitamo S, Rissanen J, Remitz A, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol. 1998;111(3):396-398.
29. El-Batawy MM, Bosseila MA, Mashaly HM, Hafez VS. Topical calcineurin inhibitors in atopic dermatitis: a systematic review and meta-analysis. J Dermatol Sci. 2009;54:76-87.
30. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis. Section 4. Prevention and flares and use of adjunctive therapies and approaches. J Am Acad Dermatol. 2014;71(8):1218-1233.
31. Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: Section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(6):327-349.
32. Krejci-Manwaring J, Tusa MG, Carroll C, et al. Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol. 2007;56:211-216.
33. Beck LA, Thaci D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371:130-139.
34. Thaçi D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016;387(10013):40-52.
35. Oldhoff J, Darsow U, Werfel T, et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy. 2005;60:693-696.
36. Jacobi A, Antoni C, Manger B, et al. Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol. 2005;52:522-526.
37. Fernández-Antón Martínez MC, Leis-Dosil V, Alfageme-Roldán F, et al. Omalizumab for the treatment of atopic dermatitis. Actas Dermosifiliogr. 2012;103:624-628.
38. Lane JE, Cheyney JM, Lane TN, et al. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol. 2006;54:68-72.
39. Krathen RA, Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol. 2005;53:338-340.
40. Belloni B, Ziai M, Lim A, et al. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol. 2007;120:1223-1225.
41. Heil PM, Maurer D, Klein B, et al. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course - a randomized, placebo-controlled and double blind pilot study. Dtsch Dermatol Ges. 2010;8:990-998.
42. Iyengar SR, Hoyte EG, Loza A, et al. Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial. Int Arch Allergy Immunol. 2013;162:89-93.
43. Sheinkopf LE, Rafi AW, Do LT, et al. Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc. 2008;29:530-537.
44. Simon D, Hosli S, Kostylina G, et al. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol. 2008;121:122-128.
45. Fernández-Antón Martínez MC, Alfageme Roldán F, Ciudad Blanco C, Suárez Fernández R. Ustekinumab in the treatment of severe atopic dermatitis: a preliminary report of our experience with 4 patients. Actas Dermosifiliogr. 2014;105:312-313.
46. Khattri S, Brunner PM, Garcet S, et al. Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis [published online June 15, 2016]. Exp Dermatol. doi:10.1111/exd.13112.
47. Gittler JK, Shemer A, Suárez-Fariñas M, et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130:1344-1354.
48. Elias PM, Steinhoff M. "Outside-to-inside" (and now back to "outside") pathogenic mechanisms in atopic dermatitis. J Invest Dermatol. 2008;128(5):1067-1070.
49. Hoffjan S, Epplen JT. The genetics of atopic dermatitis: recent findings and future options. J Mol Med (Berl). 2005;83(9):682-692.
50. Lesiak A, Kuna P, Zakrzewski M, et al. Combined occurrence of filaggrin mutations and IL-10 or IL-13 polymorphisms predisposes to atopic dermatitis. Exp Dermatol. 2011;20:491-495.
51. Kabesch M, Schedel M, Carr D, et al. IL-4/IL-13 pathway genetics strongly influence serum IgE levels and childhood asthma. J Allergy Clin Immunol. 2006;117:269-274.
52. Maier LM, Howson JM, Walker N, et al. Association of IL13 with total IgE: evidence against an inverse association of atopy and diabetes. J Allergy Clin Immunol. 2006;117:1306-1313.
53. Hackstein H, Hecker M, Kruse S, et al. A novel polymorphism in the 5′ promoter region of the human interleukin-4 receptor alpha-chain gene is associated with decreased soluble interleukin-4 receptor protein levels. Immunogenetics. 2001;53:264-269.
54. Tanaka T, Hitomi Y, Kambayashi Y, et al. The differences in the involvements of loci of promoter region and Ile50Val in interleukin-4 receptor alpha chain gene between atopic dermatitis and Japanese cedar pollinosis. Allergol Int. 2012;61:57-63.
55. Howell MD, Gao P, Kim BE, et al. The signal transducer and activator of transcription 6 gene (STAT6) increases the propensity of patients with atopic dermatitis toward disseminated viral skin infections. J Allergy Clin Immunol. 2011;128:1006-1014.
56. Howell MD, Fairchild HR, Kim BE, et al. Th2 cytokines act on S100/A11 to downregulate keratinocyte differentiation. J Invest Dermatol. 2008;128(9):2248-2258.
57. Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2007;120(1):150-155.
58. Kim BE, Leung DY, Boguniewicz M, et al. Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6. Clin Immunol. 2008;126(3):332-337.
59. Sehra S, Yao Y, Howell MD, et al. IL-4 regulates skin homeostasis and the predisposition toward allergic skin inflammation. J Immunol. 2010;184:3186-3190.
60. Hamilton JD, Suarez-Farinas M, Dhingra N, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2014;134:1293-1300.
61. Munro CS, Levell NJ, Shuster S, Friedmann PS. Maintenance treatment with cyclosporin in atopic eczema. Br J Dermatol. 1994;130:376-380.
62. Sowden JM, Berth-Jones J, Ross JS, et al. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet. 1991;338:137-140.
63. van Joost T, Heule F, Korstanje M, van den Broek MJ, Stenveld HJ, van Vloten WA. Cyclosporin in atopic dermatitis: a multicentre placebo-controlled study. Br J Dermatol. 1994;130:634-640.
64. Wahlgren CF, Scheynius A, Hagermark O. Antipruritic effect of oral cyclosporine A in atopic dermatitis. Acta Derm Venereol. 1990;70:323-329.
65. Harper JI, Ahmed I, Barclay G, et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol. 2000;142(1):52-58.
66. Salek MS, Finlay AY, Luscombe DK, et al. Cyclosporin greatly improves the quality of life of adults with severe atopic dermatitis: a randomized, double-blind, placebo-controlled trial. Br J Dermatol. 1993;129:422-430.
67. Schmitt J, Schakel K, Folster-Holst R, et al. Prednisolone vs. ciclosporin for severe adult eczema: an investigator-initiated double-blind placebo-controlled multicentre trial. Br J Dermatol. 2010;162:661-668.
68. Bemanian MH, Movahedi M, Farhoudi A, et al. High doses intravenous immunoglobulin versus oral cyclosporine in the treatment of severe atopic dermatitis. Iran J Allergy Asthma Immunol. 2005;4:139-143.
69. Granlund H, Erkko P, Remitz A, et al. Comparison of cyclosporin and UVAB phototherapy for intermittent one-year treatment of atopic dermatitis. Acta Derm Venereol. 2001;81:22-27.
70. Haeck IM, Knol MJ, Ten BO, van Velsen SG, de Bruin-Weller MS, Bruijnzeel-Koomen CA. Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. J Am Acad Dermatol. 2011;64:1074-1084.
71. Pacor ML, Di LG, Martinelli N, Mansueto P, Rini GB, Corrocher R. Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: a randomized study. Clin Exp Allergy. 2004;34:639-645.
72. Zurbriggen B, Wuthrich B, Cachelin AB, Wili PB, Kagi MK. Comparison of two formulations of cyclosporin A in the treatment of severe atopic dermatitis: a double-blind, single-centre, cross-over pilot study. Dermatology. 1999;198:56-60.
73. Czech W, Brautigam M, Weidinger G, Schopf E. A body-weight-independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life. J Am Acad Dermatol. 2000;42:653-659.
74. Zonneveld IM, De Rie MA, Beljaards RC, et al. The longterm safety and efficacy of cyclosporin in severe refractory atopic dermatitis: a comparison of two dosage regimens. Br J Dermatol. 1996;135(suppl 48):15-20.
75. Berth-Jones J, Takwale A, Tan E, et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol. 2002;147:324-330.
76. Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet. 2006;367:839-846.
77. Schram ME, Roekevisch E, Leeflang MM, Bos JD, Schmitt J, Spuls PI. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol. 2011;128:353-359.
78. Weatherhead SC, Wahie S, Reynolds NJ, Meggitt SJ. An open-label dose-ranging study of methotrexate for moderate-to-severe atopic dermatitis. Br J Dermatol. 2007;156(2): 346-351.
79. Deo M, Yung A, Hill S, Rademaker M. Methotrexate for treatment of atopic dermatitis in children and adolescents. Int J Dermatol. 2014;53:1037-1041.